understanding new changes to the ova1 results report

• Introduction of Dr. Francis and Dr. Fritsche

• Clinical Application of OVA1• The New OVA1 Results Report• Case Study• Q&A• Next Webinar

Case Study 2Agenda

How to Ask a QuestionDuring the Webinar:

1. Open the Q&A feature and place your question there

2. Depending on time remaining, the moderator will ask your question during the webinar

3. Questions that we aren’t able to get to, will be emailed to Dr. Francis and Dr. Fritsche to answer

Case Study 2Introduction

Clinical Application of OVA1

Case Study 2

New OVA1 Results Report

DRAFT

Case Study 2

New OVA1 Results ReportOVA1 measures a panel of 5 biomarkers that assesses risk of malignancy across all stages and subtypes of ovarian cancer. CA-125 is included in the panel of five biomarkers in OVA1. Since CA-125 is used to monitor multiple diseases, we have included the CA-125 value in the new OVA1 report. 

DRAFT

Case Study 2

New OVA1 Results Report

Combining powerful tools like an ultrasound can aid in the detection of ovarian cancer. The 2014 Goodrich et. al study found that imaging and the OVA1 score work together to better identify patients at higher risk of malignancy. The new OVA1 Report will now include the Goodrich graph and risk of malignancy based on levels of risk and menopausal status.

DRAFT

• 41 year old P3013• Pelvic Pain• Right sided pelvic mass• Report:

• U/S showed right ovary measuring 5.5 x 8.4 X 9.1cm• “Moderate right ovarian

enlargement. Cyst measuring 3.3 x 3.9 cm in size. There is a small amount of tissue along the posteromedial margin of this cyst over an area measuring 5mm in diameter.”

Case Study 2Case Study

Photo Courtesy: Michael D. Randell, M.D.

• OVA1 Score: 9.4 – elevated risk of malignancy

• Discussion with patient about appropriate referral to GynOnc OR prepare for surgery with Pathology available to do frozen and GynOnc on back up

• Single surgery performed• Papillary serous borderline tumor

of the ovary identified

Case Study 2Interpretation and Management

Case Study 2

New OVA1 Results Report

Physicians can now speak directly with the Director of ASPiRA Labs if they have questions about OVA1 test results by visiting www.vermillion.com or calling 1-844-ASPiRA1 to set up an appointment. We hope this clinical discussion will help you better understand OVA1 scoring and assess the best treatment plan for your patients. 

DRAFT

Case Study 2

Q&AHow to ask a questionduring the webinar:

1. Open the Q&A feature and place your question there

2. Depending on time remaining, the moderator will ask your question during the webinar

3. Questions that we aren’t able to get to, will be emailed to Dr. Francis and Dr. Fritsche to answer

Case Study 2

THANK YOUTo learn more about changes to the new OVA1 Results Report, you can:

1. Set up time to speak with your sales rep2. Email marketing@vermillion.com about

questions or supporting materials3. Schedule time with our Chief Medical Officer

and Lab Director. Email your questions to Dr. Marra Francis (mfrancis@vermillion.com) or Dr. Fritsche (hfritsche@vermillion.com).

4. Join our next webinar on December 14 from 12:30 to 12:45